Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.70 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326784 | 1.00 | CHRNB4 (0.70) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL10326293 | 1.00 | CHRNB4 (0.70) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL11455927 | 0.86 | CHRNB4 (0.52) | CHRNB4CHRNA3 | |
| SCHEMBL10326841 | 0.84 | CHRNA3 (0.56) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL10326825 | 0.84 | CHRNA3 (0.56) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL10326519 | 0.84 | CHRNA3 (0.56) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL18617333 | 0.83 | CHRNB4 (0.67) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL28601084 | 0.83 | SLC6A2 (0.78) | — | |
| SCHEMBL28601081 | 0.83 | SLC6A2 (0.78) | — | |
| SCHEMBL9241941 | 0.82 | CHRNB4 (0.70) | CHRNB4CHRNA3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822115-B2 | Nitrogen containing compounds and their use as antibacterial agents | WOCKHARDT LIMITED (IN) | 2017-11-21 | — | — | US | disclosed |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | WOCKHARDT LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | CHRNB4 1762/4885CHRNA3 1704/4885LTA4H 2091/4885 |
| US-20160355516-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS | NOS2, NOS1, NCF1 | CHRNB4 4785/4885CHRNA3 4842/4885LTA4H 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.